# STERIS plc (STE) Stock Analysis: 10.73% Potential Upside and Strong Revenue Growth Draw Investors’ Attention

- Link: https://www.directorstalkinterviews.com/steris-plc-ste-stock-analysis-10-73-potential-upside-and-strong-revenue-growth-draw-investors-attention/4121231696
- Published: 2025-12-22T11:32:30+00:00
- Author: Madison Wilson

Investors seeking opportunities in the healthcare sector may find STERIS plc (NYSE:
STE) an intriguing prospect. With its roots in infection prevention products and
services, STERIS serves a vital role across healthcare, applied sterilization technologies,
and life sciences industries. Headquartered in Mentor, Ohio, the company has expanded
its reach globally while maintaining a strong U.S. market presence.

As of the latest data, STERIS boasts a market capitalization of $25.05 billion, 
reflecting its significant presence in the medical devices industry. The stock currently
trades at $254.34, with a modest price change of 0.01%, suggesting stability amidst
market fluctuations. The 52-week range, from $202.46 to $267.99, indicates a robust
performance over the past year.

Investors should note the absence of certain valuation metrics such as trailing 
P/E, PEG ratio, and price/book, which can obscure traditional analysis. However,
the forward P/E ratio stands at 22.84, aligning with industry standards and offering
a glimpse into future earnings potential. A notable 9.90% revenue growth rate underscores
the company’s expanding market influence, while an EPS of 6.97 and a return on equity
of 10.13% highlight its profitability and efficient capital use.

STERIS’s dividend yield of 0.99% and a payout ratio of 33.52% suggest a balanced
approach to rewarding shareholders while reinvesting in growth. This is crucial 
for investors looking for both income and capital appreciation.

Analyst sentiment remains optimistic, with six buy ratings, two hold ratings, and
a single sell rating. The average target price of $281.63 presents a potential upside
of 10.73%, making STERIS an attractive option for growth-oriented investors. The
target price range varies from $231.00 to $300.00, indicating confidence in the 
company’s upward trajectory.

Technical indicators provide additional insights. The 50-day moving average of $
251.91 and a 200-day moving average of $239.37 suggest a bullish trend. However,
the RSI of 46.89 and a MACD of -0.66 may imply a need for cautious optimism, as 
these figures suggest the stock is neither overbought nor strongly trending.

STERIS’s strategic focus on infection prevention across diverse sectors positions
it well in an era where healthcare and sterilization are increasingly prioritized.
The Healthcare segment remains a cornerstone, offering a comprehensive suite of 
products and services, from surgical tables to endoscope maintenance. Meanwhile,
the Applied Sterilization Technologies segment enhances its offerings with contract
sterilization services for medical devices and pharmaceuticals. The Life Sciences
segment complements this with high-purity water systems and sterilization equipment,
serving pharmaceutical manufacturers and research institutions.

Founded in 1985, STERIS’s longstanding expertise and innovative approach continue
to drive its success. As investors weigh the potential of this healthcare stalwart,
the combination of solid revenue growth, promising analyst ratings, and a strategic
market position make STERIS a compelling candidate for portfolios focused on long-
term value in the medical devices industry.

Share on: